Boston Immune Technologies & Therapeutics

0 followers

‌

BITT has developed a platform for targeting the tumor necrosis factor receptor 2 (TNFR2) oncogene and the potent population of TNFR2 Tregs in the tumor microenvironment.

Industries

Headquarters

Stage

Employees

Links

Org chart

Russell LaMontagne

CEO

Russell LaMontagne

Collapse

David Brooks

Chief Medical Officer

VP of Manufacturing

Finance Director

Director of Legal

Director of Preclinical Development

Mohammad Razvi

Director of Clinical Operations & Development

Similar companies

Valera Health

59 followers

Abbott

194 followers

Unity

145 followers

Boston Scientific

54 followers

Cisco

1085 followers

Discover companies